Superior first-line prostate cancer treatment often not given due to ‘lack of awareness’
Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line therapies due to clinicians’ unfamiliarity with treatment guidelines and misinformation about toxicities.Numerous organizations recommend androgen receptor pathway inhibitors (ARPIs) and/or chemotherapy in combination with androgen deprivation therapy (ADT) as initial treatment for men with